Log in

Relevant bibliographies by topics / Nontuberculous mycobacterial pulmonary disease / Journal articles

Journal articles on the topic 'Nontuberculous mycobacterial pulmonary disease'

To see the other types of publications on this topic, follow the link: Nontuberculous mycobacterial pulmonary disease.

Author: Grafiati

Published: 10 December 2022

Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Nontuberculous mycobacterial pulmonary disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Falkinham, Joseph O. "The Changing Pattern of Nontuberculous Mycobacterial Disease." Canadian Journal of Infectious Diseases 14, no. 5 (2003): 281–86. http://dx.doi.org/10.1155/2003/323058.

Full text

Abstract:

Nontuberculous mycobacteria are human opportunistic pathogens whose source of infection is the environment. These include both slow-growing (eg,Mycobacterium kansasii and Mycobacterium avium) and rapid-growing (eg,Mycobacterium abscessusandMycobacterium fortuitum) species. Transmission is through ingestion or inhalation of water, particulate matter or aerosols, or through trauma. The historic presentation of pulmonary disease in older individuals with predisposing lung conditions and in children has been changing. Pulmonary disease in elderly individuals who lack the classic predisposing lung conditions is increasing. Pulmonary disease and hypersensitivity pneumonitis have been linked with occupational or home exposures to nontuberculous mycobacteria. There has been a shift fromMycobacterium scrofulaceumtoM aviumin children with cervical lymphadenitis. Further, individuals who are immunosuppressed due to therapy or HIV-infection are at a greatly increased risk for nontuberculous mycobacterial infection. The changing pattern of nontuberculous mycobacterial disease is due in part to the ability of these pathogens to survive and proliferate in habitats that they share with humans, such as drinking water. The advent of an aging population and an increase in the proportion of immunosuppressed individuals suggest that the prevalence of nontuberculous mycobacterial disease will increase.

APA, Harvard, Vancouver, ISO, and other styles

2

Jarzembowski, Jason A., and Michael B. Young. "Nontuberculous Mycobacterial Infections." Archives of Pathology & Laboratory Medicine 132, no. 8 (August 1, 2008): 1333–41. http://dx.doi.org/10.5858/2008-132-1333-nmi.

Full text

Abstract:

Abstract Context.—Nontuberculous mycobacteria include numerous acid-fast bacilli species, many of which have only recently been recognized as pathogenic. The diagnosis of mycobacterial disease is based on a combination of clinical features, microbiologic data, radiographic findings, and histopathologic studies. Objective.—To provide an overview of the clinical and pathologic aspects of nontuberculous mycobacteria infection, including diagnostic laboratory methods, classification, epidemiology, clinical presentation, and treatment. Data Sources.—Review of the pertinent literature and published methodologies. Conclusions.—Nontuberculous mycobacteria include numerous acid-fast bacilli species, many of which are potentially pathogenic, and are classified according to the Runyon system based on growth rates and pigment production. Their slow growth hinders cultures, which require special medium and prolonged incubation. Although such methods are still used, newer nucleic acid–based technologies (polymerase chain reaction and hybridization assays) can rapidly detect and speciate some mycobacteria—most notably, distinguishing Mycobacterium tuberculosis from other species. Infections caused by these organisms can present as a variety of clinical syndromes, not only in immunocompromised patients but also in immunocompetent hosts. Most common among these are chronic pulmonary infections, superficial lymphadenitis, soft tissue and osteoarticular infections, and disseminated disease. Treatment of nontuberculous mycobacterial infections is difficult, requiring extended courses of multidrug therapy with or without adjunctive surgical intervention.

APA, Harvard, Vancouver, ISO, and other styles

3

Kim, Richard D., David E. Greenberg, Mary E. Ehrmantraut, Shireen V. Guide, Li Ding, Yvonne Shea, Margaret R. Brown, et al. "Pulmonary Nontuberculous Mycobacterial Disease." American Journal of Respiratory and Critical Care Medicine 178, no. 10 (November 15, 2008): 1066–74. http://dx.doi.org/10.1164/rccm.200805-686oc.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Cowman, Steven, and Michael Loebinger. "Nontuberculous Mycobacterial Pulmonary Disease." Clinical Pulmonary Medicine 22, no. 1 (January 2015): 8–14. http://dx.doi.org/10.1097/cpm.0000000000000079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Johnson, Margaret M., Ernest Andrew Waller, and Jack P. Leventhal. "Nontuberculous mycobacterial pulmonary disease." Current Opinion in Pulmonary Medicine 14, no. 3 (May 2008): 203–10. http://dx.doi.org/10.1097/mcp.0b013e3282f9e650.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Salzer, Helmut J. F., Bakari Chitechi, Doris Hillemann, Michael Mandl, Christian Paar, Monika Mitterhumer, Bernd Lamprecht, and Florian P. Maurer. "Nontuberculous Mycobacterial Pulmonary Disease from Mycobacterium hassiacum, Austria." Emerging Infectious Diseases 26, no. 11 (November 2020): 2776–78. http://dx.doi.org/10.3201/eid2611.191718.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Banaschewski and Hofmann. "Inhaled Antibiotics for Mycobacterial Lung Disease." Pharmaceutics 11, no. 7 (July 19, 2019): 352. http://dx.doi.org/10.3390/pharmaceutics11070352.

Full text

Abstract:

Mycobacterial lung diseases are an increasing global health concern. Tuberculosis and nontuberculous mycobacteria differ in disease severity, epidemiology, and treatment strategies, but there are also a number of similarities. Pathophysiology and disease progression appear to be relatively similar between these two clinical diagnoses, and as a result these difficult to treat pulmonary infections often require similarly extensive treatment durations of multiple systemic drugs. In an effort to improve treatment outcomes for all mycobacterial lung diseases, a significant body of research has investigated the use of inhaled antibiotics. This review discusses previous research into inhaled development programs, as well as ongoing research of inhaled therapies for both nontuberculous mycobacterial lung disease, and tuberculosis. Due to the similarities between the causative agents, this review will also discuss the potential cross-fertilization of development programs between these similar-yet-different diseases. Finally, we will discuss some of the perceived difficulties in developing a clinically utilized inhaled antibiotic for mycobacterial diseases, and potential arguments in favor of the approach.

APA, Harvard, Vancouver, ISO, and other styles

8

Cowman, Steven A., Phillip James, Robert Wilson, William O. C. Cookson, Miriam F. Moffatt, and Michael R. Loebinger. "Profiling mycobacterial communities in pulmonary nontuberculous mycobacterial disease." PLOS ONE 13, no. 12 (December 11, 2018): e0208018. http://dx.doi.org/10.1371/journal.pone.0208018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Velagapudi, Manasa, Michael J. Sanley, Sumaya Ased, Chris Destache, and Mark A. Malesker. "Pharmacotherapy for nontuberculous mycobacterial pulmonary disease." American Journal of Health-System Pharmacy 79, no. 6 (November 11, 2021): 437–45. http://dx.doi.org/10.1093/ajhp/zxab422.

Full text

Abstract:

Abstract Purpose To provide an updated review of the diagnosis and pharmacotherapy of nontuberculous mycobacteria pulmonary disease (NTM-PD) and summarize guideline recommendations for an interdisciplinary treatment approach. Summary A systemic approach was taken in which all articles in English in MEDLINE and PubMed were reviewed. The US National Library of Medicine's DailyMed database was used to assess drug package inserts. Analysis of NTM treatment guidelines is summarized in the article with a focus on medications, dosing, interactions, and medication monitoring. Conclusion It is critical to manage patients with NTM with a multidisciplinary team approach. Treatment is prolonged and expensive, and the potential for drug toxicity, adverse effects, and drug interactions requires monitoring. Clinical pharmacists play a role in the management of NTM.

APA, Harvard, Vancouver, ISO, and other styles

10

Adelman, Mark H., and Doreen J. Addrizzo-Harris. "Management of nontuberculous mycobacterial pulmonary disease." Current Opinion in Pulmonary Medicine 24, no. 3 (May 2018): 212–19. http://dx.doi.org/10.1097/mcp.0000000000000473.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

To, Kimberly, Ruoqiong Cao, Aram Yegiazaryan, James Owens, and Vishwanath Venketaraman. "General Overview of Nontuberculous Mycobacteria Opportunistic Pathogens: Mycobacterium avium and Mycobacterium abscessus." Journal of Clinical Medicine 9, no. 8 (August 6, 2020): 2541. http://dx.doi.org/10.3390/jcm9082541.

Full text

Abstract:

Nontuberculous mycobacteria (NTM) are emerging human pathogens, causing a wide range of clinical diseases affecting individuals who are immunocompromised and who have underlying health conditions. NTM are ubiquitous in the environment, with certain species causing opportunistic infection in humans, including Mycobacterium avium and Mycobacterium abscessus. The incidence and prevalence of NTM infections are rising globally, especially in developed countries with declining incidence rates of M. tuberculosis infection. Mycobacterium avium, a slow-growing mycobacterium, is associated with Mycobacterium avium complex (MAC) infections that can cause chronic pulmonary disease, disseminated disease, as well as lymphadenitis. M. abscessus infections are considered one of the most antibiotic-resistant mycobacteria and are associated with pulmonary disease, especially cystic fibrosis, as well as contaminated traumatic skin wounds, postsurgical soft tissue infections, and healthcare-associated infections (HAI). Clinical manifestations of diseases depend on the interaction of the host’s immune response and the specific mycobacterial species. This review will give a general overview of the general characteristics, vulnerable populations most at risk, pathogenesis, treatment, and prevention for infections caused by Mycobacterium avium, in the context of MAC, and M. abscessus.

APA, Harvard, Vancouver, ISO, and other styles

12

Mirsaeidi, Mehdi, Maham Farshidpour, Mary Beth Allen, Golnaz Ebrahimi, and Joseph O. Falkinham. "Highlight on Advances in Nontuberculous Mycobacterial Disease in North America." BioMed Research International 2014 (2014): 1–10. http://dx.doi.org/10.1155/2014/919474.

Full text

Abstract:

Nontuberculous mycobacteria (NTM) are ubiquitous in the environment and exist as an important cause of pulmonary infections in humans. Pulmonary involvement is the most common disease manifestation of NTM and the incidence of NTM is growing in North America. Susceptibility to NTM infection is incompletely understood; therefore preventative tools are not well defined. Treatment of pulmonary nontuberculous mycobacterial (NTM) infection is difficult and entails multiple antibiotics and an extended treatment course. Also, there is a considerable variation in treatment management that should be considered before initiating treatment. We highlight the new findings in the epidemiology diagnosis and treatment of mycobacterial infections. We debate new advances regarding NTM infection in cystic fibrosis patients and solid organ transplant recipients. Finally, we introduce a new epidemiologic model for NTM disease based on virulence-exposure-host factors.

APA, Harvard, Vancouver, ISO, and other styles

13

Mitchell, John. "Surgical Management of Pulmonary Mycobacterial Disease." Seminars in Respiratory and Critical Care Medicine 39, no. 03 (June 2018): 392–98. http://dx.doi.org/10.1055/s-0038-1660474.

Full text

Abstract:

AbstractThere is renewed interest in the use of adjuvant surgical resection in the treatment of pulmonary mycobacterial disease. For pulmonary Mycobacterium tuberculosis, the emergence of significant drug resistance has led clinicians to reconsider surgery in select cases, where a clear benefit in bacterial conversion and cure has been noted. Less data exist for the use of anatomic resection in the setting of pulmonary nontuberculous mycobacterial disease, although multiple reports have supported the use of surgery in select cases. Resection is generally well tolerated, and may often be performed through a minimally invasive approach. While medical treatment clearly remains the mainstay of therapy, more research is needed regarding the use of adjuvant resection in this patient population.

APA, Harvard, Vancouver, ISO, and other styles

14

Giller, D. B., L. P. Severova, I. I. Enilenis, O. P. Frolova, and I. I. Martel. "NONTUBERCULOUS MYCOBACTERIAL PULMONARY DISEASE AND PULMONARY TUBERCULOSIS COMBINATION." Russian Electronic Journal of Radiology 11, no. 2 (2021): 227–32. http://dx.doi.org/10.21569/2222-7415-2021-11-2-227-232.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Blanc, Paul D., John R. Balmes, and Carrie Redlich. "Occupational Exposures in Nontuberculous Mycobacterial Pulmonary Disease." Chest 162, no. 2 (August 2022): e106-e107. http://dx.doi.org/10.1016/j.chest.2022.03.049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Namkoong, Ho, Atsuyuki Kurashima, Kozo Morimoto, Yoshihiko Hoshino, Naoki Hasegawa, Manabu Ato, and Satoshi Mitarai. "Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan1." Emerging Infectious Diseases 22, no. 6 (June 2016): 1116–17. http://dx.doi.org/10.3201/eid2206.151086.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Kang, Eun-Young. "Radiologic Diagnosis of Nontuberculous Mycobacterial Pulmonary Disease." Journal of the Korean Society of Radiology 82, no. 4 (2021): 838. http://dx.doi.org/10.3348/jksr.2021.0068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Hong, Su Jin, Tae Jung Kim, Jae-Ho Lee, and Jeong-Soo Park. "Nontuberculous mycobacterial pulmonary disease mimicking lung cancer." Medicine 95, no. 26 (June 2016): e3978. http://dx.doi.org/10.1097/md.0000000000003978.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Waterer, Grant. "Beyond antibiotics for pulmonary nontuberculous mycobacterial disease." Current Opinion in Pulmonary Medicine 26, no. 3 (May 2020): 260–66. http://dx.doi.org/10.1097/mcp.0000000000000665.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Colombo, Rhonda E., Suvimol C. Hill, Reginald J. Claypool, Steven M. Holland, and Kenneth N. Olivier. "Familial Clustering of Pulmonary Nontuberculous Mycobacterial Disease." Chest 137, no. 3 (March 2010): 629–34. http://dx.doi.org/10.1378/chest.09-1173.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Philley, Julie V., and David E. Griffith. "Medical Management of Pulmonary Nontuberculous Mycobacterial Disease." Thoracic Surgery Clinics 29, no. 1 (February 2019): 65–76. http://dx.doi.org/10.1016/j.thorsurg.2018.09.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Steele, Hilary P., Lisa M. Brumble, and Margaret M. Johnson. "Current Therapy for Nontuberculous Mycobacterial Pulmonary Disease." Current Treatment Options in Infectious Diseases 7, no. 4 (October 10, 2015): 342–51. http://dx.doi.org/10.1007/s40506-015-0061-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

van Ingen, Jakko. "Microbiological Diagnosis of Nontuberculous Mycobacterial Pulmonary Disease." Clinics in Chest Medicine 36, no. 1 (March 2015): 43–54. http://dx.doi.org/10.1016/j.ccm.2014.11.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Matsuyama, Masashi, Sosuke Matsumura, Mizu Nonaka, Masayuki Nakajima, Chio Sakai, Naoki Arai, Kodai Ueda, and Nobuyuki Hizawa. "Pathophysiology of pulmonary nontuberculous mycobacterial (NTM) disease." Respiratory Investigation 61, no. 2 (March 2023): 135–48. http://dx.doi.org/10.1016/j.resinv.2022.12.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Hornick, Douglas B., Charles S. Dayton, George N. Bedell, and Robert B. Fick. "Nontuberculous Mycobacterial Lung Disease." Chest 93, no. 3 (March 1988): 550–55. http://dx.doi.org/10.1378/chest.93.3.550.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Łyżwa, Ewa, Izabela Siemion-Szcześniak, Małgorzata Sobiecka, Katarzyna Lewandowska, Katarzyna Zimna, Małgorzata Bartosiewicz, Lilia Jakubowska, Ewa Augustynowicz-Kopeć, and Witold Tomkowski. "An Unfavorable Outcome of M. chimaera Infection in Patient with Silicosis." Diagnostics 12, no. 8 (July 29, 2022): 1826. http://dx.doi.org/10.3390/diagnostics12081826.

Full text

Abstract:

Mycobacterium chimaera is a slow-growing, nontuberculous mycobacterium (NTM) belonging to the Mycobacterium avium complex (MAC). It was identified as a unique species in 2004. Since 2013 it has been reported as a cause of disseminated infection in patients after cardiac surgeries. Only a few cases associated with underlying lung diseases have been noted. M. chimaera infection is characterized by ambiguous symptoms. There is no treatment with proven effectiveness, and it has a poor prognosis. Silicosis is a disease that can predispose to mycobacterial infection. Silica damages pulmonary macrophages, inhibiting their ability to kill mycobacteria. We present a case of M. chimaera infection in a patient with silicosis and without other comorbidities. To our knowledge, it is the first case of silicosis associated with M. chimaera disease. A 45-year-old man presented with a persistent low-grade fever. Based on the clinical and radiological picture, positive cultures, and histological examination, the nontuberculous mycobacterial disease was diagnosed. First, multidrug therapy according to the treatment guidelines for MAC was implemented, then antibiotics were administrated, based on drug sensitivity. Despite the treatment, eradication was not achieved and the patient died. The analysis of M. chimaera infection cases could contribute to developing recommendations and thus improve the prognosis.

APA, Harvard, Vancouver, ISO, and other styles

27

Faverio, Paola, Federica De Giacomi, Bruno Dino Bodini, Anna Stainer, Alessia Fumagalli, Francesco Bini, Fabrizio Luppi, and Stefano Aliberti. "Nontuberculous mycobacterial pulmonary disease: an integrated approach beyond antibiotics." ERJ Open Research 7, no. 2 (February 4, 2021): 00574–2020. http://dx.doi.org/10.1183/23120541.00574-2020.

Full text

Abstract:

Nontuberculous mycobacterial (NTM) pulmonary disease (PD) is an emerging condition with heterogeneous manifestations from both the microbiological and the clinical point of view. Diagnostic and therapeutic guidelines are available but there are still unmet patients' and physicians' needs, including therapy-related adverse events, symptom control, management of comorbidities, risk of re-exposure to the pathogen and unfavourable outcomes.In the present review, we provide currently available evidence for an integrated approach to NTM-PD beyond antibiotic therapy. This includes 1) avoiding exposure to environments where mycobacteria are present and careful evaluation of lifestyle and habits; 2) implementing a personalised pulmonary rehabilitation plan and airway clearance techniques to improve symptoms, exercise capacity, health-related quality of life (QoL) and functional capacity in daily living activities; 3) a nutritional evaluation and intervention to improve health-related QoL and to control gastrointestinal side-effects during antimicrobial therapy, particularly in those with low body mass index and history of weight loss; and 4) managing comorbidities that affect disease outcomes, including structural lung diseases, immune status evaluation and psychological support when appropriate.

APA, Harvard, Vancouver, ISO, and other styles

28

O’Brien, Richard J. "The Epidemiology of Nontuberculous Mycobacterial Disease." Clinics in Chest Medicine 10, no. 3 (September 1989): 407–18. http://dx.doi.org/10.1016/s0272-5231(21)00643-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Bakuła, Zofia, Aleksandra Safianowska, Magdalena Nowacka-Mazurek, Jacek Bielecki, and Tomasz Jagielski. "Short Communication: Subtyping ofMycobacterium kansasiiby PCR-Restriction Enzyme Analysis of thehsp65Gene." BioMed Research International 2013 (2013): 1–4. http://dx.doi.org/10.1155/2013/178725.

Full text

Abstract:

Mycobacterium kansasiiis one of the most common causes of pulmonary disease resulting from nontuberculous mycobacteria (NTM). It is also the most frequently isolated NTM species from clinical specimens in Poland. The aim of this study was to investigate the distribution ofM. kansasiisubtypes among patients suspected of having pulmonary NTM disease. Fifty clinical isolates ofM. kansasiirecovered from as many patients with suspected mycobacterial lung disease between 2000 and 2010 in Poland were genotyped by PCR-restriction enzyme analysis (PCR-REA) of partialhsp65gene.Mycobacterium kansasiisubtype I was the only genotype to be identified among the isolates, both disease-associated and non-disease-associated. Isolation ofM. kansasiisubtype I from clinical specimens may be indicative of infection but may also merely represent colonization.

APA, Harvard, Vancouver, ISO, and other styles

30

Daley, Charles L., Jonathan M. Iaccarino, Christoph Lange, Emmanuelle Cambau, Richard J. Wallace, Claire Andrejak, Erik C. Böttger, et al. "Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline." Clinical Infectious Diseases 71, no. 4 (August 14, 2020): 905–13. http://dx.doi.org/10.1093/cid/ciaa1125.

Full text

Abstract:

Abstract Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.

APA, Harvard, Vancouver, ISO, and other styles

31

Daley, Charles L., Jonathan M. Iaccarino, Christoph Lange, Emmanuelle Cambau, Richard J. Wallace, Claire Andrejak, Erik C. Böttger, et al. "Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline." Clinical Infectious Diseases 71, no. 4 (July 6, 2020): e1-e36. http://dx.doi.org/10.1093/cid/ciaa241.

Full text

Abstract:

Abstract Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.

APA, Harvard, Vancouver, ISO, and other styles

32

Daley, Charles L., Jonathan M. Iaccarino, Christoph Lange, Emmanuelle Cambau, Richard J. Wallace, Claire Andrejak, Erik C. Böttger, et al. "Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline." European Respiratory Journal 56, no. 1 (July 2020): 2000535. http://dx.doi.org/10.1183/13993003.00535-2020.

Full text

Abstract:

Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.

APA, Harvard, Vancouver, ISO, and other styles

33

Winthrop, Kevin L., Erin McNelley, Brian Kendall, Allison Marshall-Olson, Christy Morris, Maureen Cassidy, Ashlen Saulson, and Katrina Hedberg. "Pulmonary Nontuberculous Mycobacterial Disease Prevalence and Clinical Features." American Journal of Respiratory and Critical Care Medicine 182, no. 7 (October 2010): 977–82. http://dx.doi.org/10.1164/rccm.201003-0503oc.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Szymanski, Eva P., Janice M. Leung, Cedar J. Fowler, Carissa Haney, Amy P. Hsu, Fei Chen, Priya Duggal, et al. "Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease." American Journal of Respiratory and Critical Care Medicine 192, no. 5 (September 2015): 618–28. http://dx.doi.org/10.1164/rccm.201502-0387oc.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Fukuoka, Toshihiko, Kozo Morimoto, Tomoyuki Ogata, and Kazuhiro Uchimura. "Health checkup system and pulmonary nontuberculous mycobacterial disease." Respiratory Investigation 55, no. 6 (November 2017): 376–79. http://dx.doi.org/10.1016/j.resinv.2017.08.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Holt, Michael R., Shannon H. Kasperbauer, and Charles L. Daley. "Serial sputum induction in nontuberculous mycobacterial pulmonary disease." European Respiratory Journal 55, no. 6 (March 12, 2020): 1902196. http://dx.doi.org/10.1183/13993003.02196-2019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Koh, Won-Jung, and O. Jung Kwon. "Treatment of Nontuberculous Mycobacterial Pulmonary Diseases." Tuberculosis and Respiratory Diseases 56, no. 1 (2004): 5. http://dx.doi.org/10.4046/trd.2004.56.1.5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Kikuchi, Toshiaki, Takuro Sakagami, and Hiroshi Moro. "Update in Nontuberculous Mycobacterial Pulmonary Diseases." Nihon Naika Gakkai Zasshi 107, no. 2 (February 10, 2018): 292–97. http://dx.doi.org/10.2169/naika.107.292.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

López, Arístides, Fermin Acosta, Dilcia Sambrano, Musharaf Tarajia, Sophia Navajas, Florentino Arias, Baudilio Escobar, Porfirio Ortis, Fidel Adames, and Amador Goodridge. "Direct Molecular Characterization of Acid-Fast Bacilli Smear of Nontuberculosis Mycobacterium Species Causing Pulmonary Tuberculosis in Guna Yala Region, Panama." American Journal of Tropical Medicine and Hygiene 105, no. 3 (September 15, 2021): 633–37. http://dx.doi.org/10.4269/ajtmh.21-0096.

Full text

Abstract:

ABSTRACT. Mycobacterium tuberculosis (MTB) stands out as the main causative agent of pulmonary tuberculosis (TB). However, nontuberculous mycobacteria (NTM) species also have the potential to infect and cause TB in susceptible individuals. The objective of this study was to identify NTM species that cause public health problems in remote areas. The study was carried out using 105 sputum smears obtained from patients from the Guna Yala Region of Panama with clinical signs suggestive of TB. DNA was extracted from sputum smears. Nontuberculous mycobacteria and MTB were characterized using polymerase chain reaction restriction analysis (hsp65, rpob) and an evaluation of 24-mycobacterial interspersed repetitive units–variable number of tandem repeats loci. Twenty-six Mycobacterium species were characterized; 19 (18%) were identified as MTB, and 7 (6.7%) were identified as NTM (four M. avium complex, two M. haemophilum, one M. tusciae). These results suggest that at least one in five cases of pulmonary TB among this population is caused by an NTM. Thus, identifying the bacteria causing pulmonary disease is key even in remote regions of the world where standard diagnosis and culture are not available. Strengthening the laboratory capacity within the Guna Yala Region is needed to identify NTM infections promptly.

APA, Harvard, Vancouver, ISO, and other styles

40

Kumar, Kartik, Charles L. Daley, David E. Griffith, and Michael R. Loebinger. "Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments." European Respiratory Review 31, no. 163 (February 9, 2022): 210212. http://dx.doi.org/10.1183/16000617.0212-2021.

Full text

Abstract:

Nontuberculous mycobacterial pulmonary disease (NTM-PD) remains a challenging condition to diagnose and treat effectively. Treatment of NTM-PD is prolonged, frequently associated with adverse effects and has variable success. In this review, we consider the factors influencing clinicians when treating NTM-PD and discuss outcomes from key studies on the pharmacological management of Mycobacterium avium complex pulmonary disease and M. abscessus pulmonary disease. We highlight issues relating to treatment-related toxicity and provide an overview of repurposed and emerging therapies for NTM-PD.

APA, Harvard, Vancouver, ISO, and other styles

41

Marras, Theodore K., Michael A. Campitelli, Jeffrey C. Kwong, Hong Lu, Sarah K. Brode, Alex Marchand-Austin, Andrea S. Gershon, and Frances B. Jamieson. "Risk of nontuberculous mycobacterial pulmonary disease with obstructive lung disease." European Respiratory Journal 48, no. 3 (June 10, 2016): 928–31. http://dx.doi.org/10.1183/13993003.00033-2016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Catanzaro, Antonino, and Charles L. Daley. "Lung disease due to nontuberculous mycobacterial infections." Clinics in Chest Medicine 23, no. 3 (September 2002): xi—xii. http://dx.doi.org/10.1016/s0272-5231(02)00037-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Griffith, David E. "Update: Management of Nontuberculous Mycobacterial Disease." Clinical Pulmonary Medicine 7, no. 5 (September 2000): 239–44. http://dx.doi.org/10.1097/00045413-200007050-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Thomas, Benjamin S., and Koh Okamoto. "Role of Race/Ethnicity in Pulmonary Nontuberculous Mycobacterial Disease." Emerging Infectious Diseases 21, no. 3 (March 2015): 544–45. http://dx.doi.org/10.3201/eid2103.141369.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Ringshausen, Felix C., Dirk Wagner, Andrés de Roux, Roland Diel, David Hohmann, Lennart Hickstein, Tobias Welte, and Jessica Rademacher. "Prevalence of Nontuberculous Mycobacterial Pulmonary Disease, Germany, 2009–2014." Emerging Infectious Diseases 22, no. 6 (June 2016): 1102–5. http://dx.doi.org/10.3201/eid2206.151642.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Nguyen, Ivy, ONeil Green, and Lucy Modahl. "Nontuberculous Mycobacterial Pulmonary Disease: A Clinical and Radiologic Update." Seminars in Roentgenology 57, no. 1 (January 2022): 75–89. http://dx.doi.org/10.1053/j.ro.2021.10.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Winthrop, Kevin, Andrea Rivera, Flora Engelmann, Sasha Rose, Anne Lewis, Jennifer Ku, Luiz Bermudez, and Ilhem Messaoudi. "A Rhesus Macaque Model of Pulmonary Nontuberculous Mycobacterial Disease." American Journal of Respiratory Cell and Molecular Biology 54, no. 2 (February 2016): 170–76. http://dx.doi.org/10.1165/rcmb.2015-0256rc.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Wyrostkiewicz, Dorota, Lucyna Opoka, Dorota Filipczak, Ewa Jankowska, Wojciech Skorupa, Ewa Augustynowicz-Kopeć, and Monika Szturmowicz. "Nontuberculous Mycobacterial Lung Disease in the Patients with Cystic Fibrosis—A Challenging Diagnostic Problem." Diagnostics 12, no. 7 (June 21, 2022): 1514. http://dx.doi.org/10.3390/diagnostics12071514.

Full text

Abstract:

Background: Cystic fibrosis (CF) is an autosomal, recessive genetic disorder, caused by a mutation in the cystic fibrosis transmembrane conductance receptor regulator (CFTR) gene. Dysregulated mucous production, and decreased bronchial mucociliary clearance, results in increased susceptibility to bacterial and fungal infections. Recently, nontuberculous mycobacteria (NTM) infections were identified as an emerging clinical problem in CF patients. Aim: The aim of the present study was to assess the frequency of NTM isolations in CF patients hospitalized in the pulmonary department, serving as a hospital CF center, and to describe challenges concerning the recognition of NTMLD (nontuberculous mycobacterial lung disease) in those patients. Methods: Consecutive CF patients, who were hospitalized due to pulmonary exacerbations (PEX), in a single CF center, between 2010 and 2020, were retrospectively assessed for the presence of NTM in respiratory specimens. Clinical and radiological data were retrospectively reviewed. Results: Positive respiratory specimen cultures for NTM were obtained in 11 out of 151 patients (7%), mean age—35.7 years, mean BMI—20.2 kg/m2, mean FEV1—58.6% pred. Cultures and phenotyping revealed the presence of Mycobacterium avium (M. avium)—in six patients, Mycobacterium chimaera (M. chimaera) in two, Mycobacterium kansasii (M. kansasii)—in one, Mycobacterium abscessus (M. abscessus)—in one, Mycobacterium lentifavum (M. lentiflavum)—in one. Simultaneously, respiratory cultures were positive for fungi in 91% of patients: Candida albicans (C. albicans)—in 82%, Aspergillus fumigatus (A. fumigatus)—in 45%. Clinical signs of NTMLD were non—specific, chest CT indicated NTMLD in five patients only. Conclusion: Due to non-specific clinical presentation, frequent sputum cultures for NTM and analysis of serial chest CT examinations are crucial for NTMLD recognition in CF patients. Further studies concerning the predictive role of fungal pathogens for NTMLD development in CF patients are needed.

APA, Harvard, Vancouver, ISO, and other styles

49

Daniel-Wayman, Shelby, Emily Ricotta, D. Prevots, and Jennifer Adjemian. "Epidemiology of Nontuberculous Mycobacteriosis." Seminars in Respiratory and Critical Care Medicine 39, no. 03 (June 2018): 325–35. http://dx.doi.org/10.1055/s-0038-1651491.

Full text

Abstract:

AbstractAnnual prevalence estimates for pulmonary nontuberculous mycobacterial (PNTM) disease in the contiguous United States range from 1.4 to 13.9 per 100,000 persons, while one study found an annual prevalence of up to 44 per 100,000 persons in Hawaii. PNTM prevalence varies by region, sex, and race/ethnicity, with higher prevalence among women and persons of Asian ancestry, as well as in the Southern United States and Hawaii. Studies consistently indicate that PNTM prevalence is increasing, with estimates ranging from 2.5 to 8% per year. Most PNTM disease is associated with Mycobacterium avium complex (MAC), although the proportion of disease attributed to MAC varies by region. Host factors identified as influencing disease risk include structural lung disease, immunomodulatory medication, as well as variants in connective tissue, mucociliary clearance, and immune genes. Environmental variables including measures of atmospheric moisture and concentrations of certain soil factors have also been shown to correlate with higher PNTM prevalence. Prevalence of extrapulmonary NTM disease is lower, stable, and associated with different risk factors, including primary immune deficiencies or HIV infection.

APA, Harvard, Vancouver, ISO, and other styles

50

Tan, Shera, and Shannon Kasperbauer. "Nontuberculous Mycobacteria." Seminars in Respiratory and Critical Care Medicine 42, no. 04 (July 14, 2021): 567–86. http://dx.doi.org/10.1055/s-0041-1730997.

Full text

Abstract:

AbstractNontuberculous mycobacteria (NTM) are ubiquitous in the environment and 193 species of NTM have been discovered thus far. NTM species vary in virulence from benign environmental organisms to difficult-to-treat human pathogens. Pulmonary infections remain the most common manifestation of NTM disease in humans and bronchiectasis continues to be a major risk factor for NTM pulmonary disease (NTM PD). This article will provide a useful introduction and framework for clinicians involved in the management of bronchiectasis and NTM. It includes an overview of the epidemiology, pathogenesis, diagnosis, and management of NTM PD. We will address the challenges faced in the diagnosis of NTM PD and the importance of subspeciation in guiding treatment and follow-up, especially in Mycobacterium abscessus infections. The treatment of both Mycobacterium avium complex and M. abscessus, the two most common NTM species known to cause disease, will be discussed in detail. Elements of the recent ATS/ERS/ESCMID/IDSA NTM guidelines published in 2020 will also be reviewed.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!